- Home
- ALVO vs APLS Comparison
ALVO vs APLS Comparison
Compare ALVO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- APLS
- Stock Information
- Founded
- ALVO 2013
- APLS 2009
- Country
- ALVO Luxembourg
- APLS United States
- Employees
- ALVO N/A
- APLS N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- APLS Health Care
- Exchange
- ALVO Nasdaq
- APLS Nasdaq
- Market Cap
- ALVO 2.5B
- APLS 2.2B
- IPO Year
- ALVO N/A
- APLS 2017
- Fundamental
- Price
- ALVO $9.35
- APLS $17.69
- Analyst Decision
- ALVO Buy
- APLS Buy
- Analyst Count
- ALVO 1
- APLS 19
- Target Price
- ALVO $18.00
- APLS $37.67
- AVG Volume (30 Days)
- ALVO 229.9K
- APLS 2.1M
- Earning Date
- ALVO 08-14-2025
- APLS 07-31-2025
- Dividend Yield
- ALVO N/A
- APLS N/A
- EPS Growth
- ALVO N/A
- APLS N/A
- EPS
- ALVO 0.34
- APLS N/A
- Revenue
- ALVO $587,890,000.00
- APLS $775,839,000.00
- Revenue This Year
- ALVO $35.07
- APLS $1.01
- Revenue Next Year
- ALVO $44.61
- APLS $22.14
- P/E Ratio
- ALVO $27.70
- APLS N/A
- Revenue Growth
- ALVO 413.92
- APLS 48.04
- 52 Week Low
- ALVO $7.35
- APLS $16.10
- 52 Week High
- ALVO $13.79
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- ALVO 41.18
- APLS 42.98
- Support Level
- ALVO $10.32
- APLS $18.26
- Resistance Level
- ALVO $11.85
- APLS $19.96
- Average True Range (ATR)
- ALVO 0.46
- APLS 0.84
- MACD
- ALVO -0.23
- APLS -0.08
- Stochastic Oscillator
- ALVO 19.87
- APLS 19.22
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.